DE69840216D1 - Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden - Google Patents

Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden

Info

Publication number
DE69840216D1
DE69840216D1 DE69840216T DE69840216T DE69840216D1 DE 69840216 D1 DE69840216 D1 DE 69840216D1 DE 69840216 T DE69840216 T DE 69840216T DE 69840216 T DE69840216 T DE 69840216T DE 69840216 D1 DE69840216 D1 DE 69840216D1
Authority
DE
Germany
Prior art keywords
cell
prodrug
endogenous
preparations
biological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69840216T
Other languages
English (en)
Inventor
Michael H Shepard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celmed Oncology USA Inc
Original Assignee
Celmed Oncology USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celmed Oncology USA Inc filed Critical Celmed Oncology USA Inc
Application granted granted Critical
Publication of DE69840216D1 publication Critical patent/DE69840216D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
DE69840216T 1997-08-08 1998-08-07 Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden Expired - Lifetime DE69840216D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5552597P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
DE69840216D1 true DE69840216D1 (de) 2008-12-24

Family

ID=21998430

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69840216T Expired - Lifetime DE69840216D1 (de) 1997-08-08 1998-08-07 Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden

Country Status (9)

Country Link
US (3) US6495553B1 (de)
EP (1) EP1004022A4 (de)
JP (3) JP2001512830A (de)
CN (1) CN1307421C (de)
AT (1) ATE413881T1 (de)
AU (1) AU9016998A (de)
CA (1) CA2298681C (de)
DE (1) DE69840216D1 (de)
WO (1) WO1999008110A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9016998A (en) * 1997-08-08 1999-03-01 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
US6703374B1 (en) 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CN1192102C (zh) 1998-01-23 2005-03-09 新生物生物公司 酶催化的治疗剂
BR0012677A (pt) * 1999-07-22 2003-07-01 Newbiotics Inc Ativação terapêutica catalisada por enzima
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
JP2003525866A (ja) 1999-07-22 2003-09-02 ニューバイオティックス インコーポレイテッド 治療抵抗性腫瘍を処置するための方法
US20030212037A1 (en) * 2000-12-21 2003-11-13 Christopher Boyer Use of bvdu for inhibiting the growth of hyperproliferative cells
US7514067B2 (en) * 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
WO2002007780A2 (en) * 2000-07-20 2002-01-31 Newbiotics, Inc. Methods for identifying therapeutic targets
EP1683874A3 (de) * 2000-08-29 2006-10-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Verfahren zur Isolierung von Genen, die für Proteine mit spezifischer Funktion kodieren, und zur Auslese von pharmazeutisch aktiven Wirkstoffen
US7138388B2 (en) 2001-01-19 2006-11-21 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
WO2002089739A2 (en) 2001-05-09 2002-11-14 Newbiotics, Inc. Peptide deformylase activated prodrugs
US20040235761A1 (en) * 2001-08-14 2004-11-25 Yousuke Furuta Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
EP1492523A2 (de) * 2001-11-23 2005-01-05 Chugai Seiyaku Kabushiki Kaisha Verfahren zur bestimmung von enzymen die tumoren als ziel haben
US20030152747A1 (en) * 2002-01-11 2003-08-14 The Garland Company, Inc., An Ohio Corporation Roofing materials
JP4502641B2 (ja) * 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド 抗癌組み合わせおよびその使用方法
US6987180B2 (en) 2002-02-07 2006-01-17 President And Fellows Of Harvard College Uridine analogs and techniques for making and using
EP1551990A4 (de) * 2002-06-18 2006-12-06 Irm Llc Diagnose und behandlung chemoresistenter tumoren
EP1585751A4 (de) 2002-11-14 2008-08-13 Celmed Oncology Usa Inc Peptiddeformylase-aktivierte prodrugs
EP1599484A2 (de) * 2003-02-21 2005-11-30 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung von hexacyclischen camptothecin derivaten
TWI351284B (en) * 2004-04-09 2011-11-01 Chugai Pharmaceutical Co Ltd Novel water-soluble prodrugs
AU2005247943A1 (en) * 2004-05-23 2005-12-08 Gerard M. Housey Theramutein modulators
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
EP1938823A1 (de) * 2005-10-19 2008-07-02 Chugai Seiyaku Kabushiki Kaisha Mittel zur prävention oder behandlung von pankreaskarzinom, ovarialkarzinom oder leberkarzinom mit einem neuen wasserlöslichen prodrug
US8877785B2 (en) 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
CN113917023B (zh) * 2021-10-08 2024-03-19 湖南慧泽生物医药科技有限公司 测定人血浆中溴夫定浓度的方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US49201A (en) * 1865-08-01 Improved composition for paint
US668A (en) * 1838-04-02 Improvement in wardrobe-bedsteads
US95921A (en) * 1869-10-19 Horace a
US119094A (en) * 1871-09-19 Improvement in bungs and bung-inserters
US165199A (en) * 1875-07-06 Improvement in eyeglasses
US22001A (en) * 1858-11-02 Billiard-table
US34473A (en) * 1862-02-25 Improved digging-machine
GB982776A (en) 1962-01-24 1965-02-10 Wellcome Found 2-deoxyuridines and their use in pharmaceutical compositions having anti-immune activity
JPS5017989B1 (de) 1970-12-24 1975-06-25
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US4247544A (en) 1979-07-02 1981-01-27 The Regents Of The University Of California C-5 Substituted uracil nucleosides
JPS5843993A (ja) 1981-09-09 1983-03-14 Yamasa Shoyu Co Ltd １−β−Ｄ−アラビノフラノシル−（Ｅ）−５−（２−ハロゲノビニル）ウラシル−５′−りん酸およびその製造法
EP0095294A1 (de) 1982-05-22 1983-11-30 Beecham Group Plc Deoxyuridin-Derivate, ihre Herstellungsverfahren und ihre medizinische Anwendung
DE3229169A1 (de) 1982-08-05 1984-02-09 Robugen GmbH Pharmazeutische Fabrik, 7300 Esslingen Verwendung von 5-alkylpyrimidinnukleosiden und deren derivate als zytostatika
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US5116827A (en) 1986-10-23 1992-05-26 American Cyanamid Company Quinolinecarboxylic acid derivatives as solubilized pro-drugs
US5077283A (en) 1986-10-23 1991-12-31 American Cyanamid Company Solubilized imidazole pro-drugs
US5070082A (en) 1986-10-23 1991-12-03 American Cyanamid Company Solubilized pro-drugs
US5212291A (en) 1986-10-23 1993-05-18 American Cyanamid Company Anthracycline derivatives as solubilized pro-drugs
US5077282A (en) 1986-10-23 1991-12-31 American Cyanamid Company Solubilized pro-drugs
US5116822A (en) * 1986-10-24 1992-05-26 Stichting Rega Vzw Therapeutic application of dideoxycytidinene
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
NL8700366A (nl) 1987-02-13 1988-09-01 Stichting Rega V Z W Combinatie van fu met bvdu als middel tegen adenocarcinoom.
US5085983A (en) 1988-08-19 1992-02-04 City Of Hope Detection of human tumor progression and drug resistance
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
CA1317291C (en) 1987-12-14 1993-05-04 Naeem Botros Hanna Antitumor 6-sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides and related compounds
DE68917479D1 (de) * 1988-02-24 1994-09-15 Inst Rech Chim Biolog Derivate von deoxy-2'-uridin substituiert in der 5, 3' oder 5' stellung durch acylierte alpha-amino-gruppen, verfahren zur herstellung und arzneimittel daraus.
WO1990003978A1 (en) 1988-10-03 1990-04-19 Stichting Rega Vzw 5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application
CA2071907C (en) * 1989-12-20 2000-08-08 Kevin W. Moore Bcrf1 proteins as inhibitors of interferon-y
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9010242D0 (en) 1990-05-08 1990-06-27 British Telecomm Optical signal regenerator and optical communications system incorporating same
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5556942A (en) * 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
SK279262B6 (sk) 1991-05-16 1998-08-05 Glaxo Group Limited Protivírusová zmes, farmaceutický prostriedok s je
US5233031A (en) 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
US5274162A (en) * 1991-12-13 1993-12-28 Arnold Glazier Antineoplastic drugs with bipolar toxification/detoxification functionalities
EP0619736A1 (de) 1991-12-31 1994-10-19 Worcester Foundation For Biomedical Research, Inc. Antiparasitäre Oligonucleotide mit einer Wirkung gegen arzneimittelrestistenteMalaria
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5409632A (en) * 1992-11-16 1995-04-25 The Procter & Gamble Company Cleaning and bleaching composition with amidoperoxyacid
IL105244A (en) * 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
EP0720615B1 (de) 1993-09-21 2000-07-26 Amersham Pharmacia Biotech UK Limited Elongation, amplifikation und sequenzierung unter verwendung eines chimären oligonucleotids
US5457187A (en) * 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5521161A (en) 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
JPH07264309A (ja) * 1994-03-18 1995-10-13 Fujitsu Ltd 着信制御装置
GB9415167D0 (en) * 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5968910A (en) * 1994-11-30 1999-10-19 Jan M. R. Balzarini Compositions containing two or three inhibitors of different HIV reverse transcriptases
DK0806956T3 (da) * 1995-02-01 2003-01-06 Resprotect Gmbh Anvendelse af 5-substituerede nucleosider til hæmning af resistensdannelse ved cytostatikabehandling
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
IL117940A (en) 1995-04-19 2003-06-24 Kumiai Chemical Industry Co Benzylsulfide derivatives, process for their production and insecticide compositions containing them
US5856464A (en) 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
US5998151A (en) * 1995-12-01 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase
WO1997021452A2 (en) 1995-12-14 1997-06-19 Advanced Magnetics, Inc. Macromolecular prodrugs of nucleotide analogs
AU1846297A (en) 1996-01-31 1997-08-22 Regents Of The University Of California, The Method for inhibiting tumor cell growth
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
WO1999006072A1 (en) 1997-07-30 1999-02-11 Boehringer Mannheim Corporation Cyclized prodrugs
AU9016998A (en) * 1997-08-08 1999-03-01 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
CA2307807C (en) 1997-10-23 2008-09-02 Andrea G. Bodnar Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
AU758426B2 (en) 1997-10-30 2003-03-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleosides for imaging and treatment applications
US6703374B1 (en) * 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
CN1192102C (zh) * 1998-01-23 2005-03-09 新生物生物公司 酶催化的治疗剂
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US20020147175A1 (en) * 2000-11-16 2002-10-10 Shepard H. Michael Synergistic ECTA compositions
US7138388B2 (en) * 2001-01-19 2006-11-21 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
JP3813490B2 (ja) 2001-10-30 2006-08-23 富士通株式会社 スペクトラム拡散レイク受信機

Also Published As

Publication number Publication date
ATE413881T1 (de) 2008-11-15
US20050123983A1 (en) 2005-06-09
EP1004022A4 (de) 2000-10-25
JP2002167337A (ja) 2002-06-11
EP1004022A1 (de) 2000-05-31
CA2298681C (en) 2008-07-08
US6495553B1 (en) 2002-12-17
AU9016998A (en) 1999-03-01
CN1265741A (zh) 2000-09-06
US7465734B2 (en) 2008-12-16
US20010016329A1 (en) 2001-08-23
JP2001512830A (ja) 2001-08-28
CA2298681A1 (en) 1999-02-18
CN1307421C (zh) 2007-03-28
JP2002223790A (ja) 2002-08-13
WO1999008110A1 (en) 1999-02-18

Similar Documents

Publication Publication Date Title
DE69840216D1 (de) Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
BR9907736A (pt) Agentes terapêuticos catalisados por enzima
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
Baker et al. The mouse sperm proteome characterized via IPG strip prefractionation and LC‐MS/MS identification
Yan et al. Mitochondrial adenine nucleotide translocase is modified oxidatively during aging
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
WO2005040758A3 (en) Use of pirfenidone in therapeutic regimens
DE69432934D1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
CY1107715T1 (el) Διαγνωση και αγωγη του καρκινου του προστατη
BR0115715A (pt) Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
WO2005010215A3 (en) Methods for identifying tolerance modulatory compounds and uses therefor
DK1590467T3 (da) Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler
Milton et al. Epithelial-mesenchymal transition and H2O2 signaling–a driver of disease progression and a vulnerability in cancers
WO2004005530A3 (en) Compositions and methods for treatment and detection of multiple cancers
DE60132443D1 (de) In lebenden zielzellen
Gomes et al. The murine cardiac 26S proteasome: an organelle awaiting exploration
Feng et al. Senescence marker protein‐30 as a novel antiaging molecule
WO2004039312A3 (en) Optineurin and glaucoma
EP1240922A3 (de) Verfahren und Zusammensetzungen zu Überwinden des Widerstands gegen biologische oder chemische Therapie
Fang et al. Purealin blocks the sliding movement of sea urchin flagellar axonemes by selective inhibition of half the ATPase activity of axonemal dyneins
Haider et al. Opposing Interplay between Nuclear Factor Erythroid 2-Related Factor 2 and Forkhead BoxO 1/3 is Responsible for Sepantronium Bromide’s Poor Efficacy and Resistance in Cancer cells: Opportunity for Combination Therapy in Triple Negative Breast Cancer
HUP0303286A2 (hu) Készítmények és eljárások biológiai információ felismerésére és szelektálására
Tuma Pancreatic Cancer Conference Shows a Field in Transition
ATE296106T1 (de) Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc

Legal Events

Date Code Title Description
8364 No opposition during term of opposition